Drug Profile
Research programme: diabetic retinopathy therapy - Quark Biotech
Latest Information Update: 03 Apr 2007
Price :
$50
*
At a glance
- Originator Quark Biotech
- Class
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic retinopathy
Most Recent Events
- 03 Apr 2007 Discontinued - Preclinical for Diabetic retinopathy in USA (Ophthalmic)
- 16 Mar 2005 The programme is available for licensing (http://www.quarkbiotech.com)
- 15 Mar 2005 Preclinical trials in Diabetic retinopathy in USA (Ophthalmic)